August 17th 2025
Experts discussed talquetamab's unique mechanism and favorable patient outcomes in relapsed/refractory multiple myeloma.
Bispecific Therapies in Multiple Myeloma: Impact on Real-World Practice
November 14th 2023Experts share how the availability of three new bispecific therapies has transformed myeloma patient care, offering a lifeline to those previously without treatment options and showcasing positive responses in various patient populations.
DREAMM-3: Belantamab Mafodotin in Patients With Relapsed/Refractory MM
Craig Cole, MD, reviews data from DREAMM-3 on the efficacy and safety of single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma.
Cross Q&A: Clinical Application of Ixa-Len-Dex for Patients With MM
Experts on multiple myeloma discuss the clinical applications of ixazomib-lenalidomide-dexamethasone combination therapy.
Teclistamab Plus Talquetamab in RRMM: Data from the RedirecTT-1 Study
November 9th 2023Joselle Cook, M.B.B.S., discusses the RedirecTT-1 trial combining teclistamab and talquetamab for patients with relapsed/refractory multiple myeloma, noting high response rates even in high-risk myeloma but concerns about long-term resistance.
Talquetamab in RRMM: Results From MonumenTAL-1
November 9th 2023Dr Binod Dhakal discusses response rates and toxicities seen with recently approved bispecific antibodies talquetamab in patients with heavily pretreated multiple myeloma, noting high response rates even after CAR-T, but also unique side effects.
Bispecific Therapies in RRMM: Teclistamab, Talquetamab, and Elranatamab Updates
November 7th 2023Insight into the latest updates on three approved bispecific therapies in the context of relapsed and refractory multiple myeloma, including teclistamab, talquetamab, and elranatamab, discussing response rates, administration, and side effects.
REMIX: Real-World Effectiveness of Ixazomib with Lenalidomide and Dexamethasone in MM
Faiz Answer, MD, FACP, reviews data from the REMIX study on the real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma.
Cross Q&A: Retrospective Study of Patients With MM
Experts in the field of multiple myeloma discuss data from a retrospective study on patients with multiple myeloma.
Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
November 2nd 2023Dr Luciano Costa discusses treatment options for patients with multiple myeloma with early vs late relapse, noting that those with early aggressive relapse have limited options and often rapidly exhaust available therapies, emphasizing the need for newer agents like bispecific antibodies.
Outcomes After Biochemical or Clinical Progression in Patients with MM
Jeffrey A. Zonder, MD, reviews data on patient outcomes following biochemical or clinical progression in multiple myeloma.
Cross Q&A: Efficacy of CAR T-Cell Therapy in MM
The expert panel discusses the efficacy and durability of response of ciltacabtagene autoleucel in patients with multiple myeloma.
CARTITUDE-4: Cilta-Cel in Lenalidomide-Refractory MM
Jack Khouri, MD, discusses phase 3 results from the CARTITUDE-4 study investigating ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.
Cross Q&A: Treatment Considerations for Ixa-Pom-Dex in Multiple Myeloma
Following a review of data from the ALLIANCE A061202 study, experts on multiple myeloma discuss treatment considerations for patients being treated with ixazomib, pomalidomide, and dexamethasone.
ALLIANCE A061202: Ixazomib Plus Pomalidomide and Dexamethasone in Multiple Myeloma
Andrew Kin, MD, reviews data on the addition of ixazomib to pomalidomide and dexamethasone in patients with multiple myeloma who progressed on lenalidomide in the first line.